The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced on Thursday ...

The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.

On December 19, 2025, the Centers for Medicare & Medicaid Services (CMS) released GLOBE (Global Benchmark for Efficient Drug Pricing Model) and GUARD (Guarding U.S. Medicare Against Rising Drug Costs) ...

The Centers for Medicare & Medicaid Services has announced the selection of 15 prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program. These are high-cost drugs covered ...

The Centers for Medicare & Medicaid Services has postponed its BALANCE pilot program for GLP‑1 obesity drug coverage until at least 2027 after insurers balked at costs and risks. In its place, CMS ...

As our population continues to age, Medicare’s role in the American health care system continues to grow. And Medicare’s power goes beyond health care; it was the power of the Medicare program that ...